SARA KOENIG LANGSTON: Open Payments
NPI 1265095061 · NEW BRAUNFELS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$24,914 in 130 payments from 13 companies in 2025. Trend: 2023 $862 · 2024 $1,082 · 2025 $24,914
Speaker / faculty: $16,420Consulting: $4,380Food & beverage: $2,621Travel & lodging: $1,493
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 53 | $23,375 |
| Lundbeck LLC | 15 | $303 |
| Otsuka America Pharmaceutical, Inc. | 14 | $252 |
| E.R. Squibb & Sons, L.L.C. | 12 | $207 |
| Janssen Pharmaceuticals, Inc | 7 | $157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $118 |
| Neurocrine BioSciences, Inc. | 6 | $116 |
| Teva Pharmaceuticals USA, Inc. | 5 | $109 |
| Axsome Therapeutics, Inc. | 5 | $96 |
| Vanda Pharmaceuticals Inc. | 3 | $79 |
Products named: LYBALVI, REXULTI, ABILIFY ASIMTUFII, COBENFY, ARISTADA, CAPLYTA, INGREZZA, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
